Page last updated: 2024-10-27

flutamide and Weight Gain

flutamide has been researched along with Weight Gain in 4 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Weight Gain: Increase in BODY WEIGHT over existing weight.

Research Excerpts

ExcerptRelevanceReference
" We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone."9.09Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. ( Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP, 2000)
"Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both."6.68A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. ( Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP, 1996)
" We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone."5.09Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. ( Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP, 2000)
"Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both."2.68A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. ( Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP, 1996)
"Flutamide treatment for 4 weeks resulted in decreased organ weights of the epididymides and prostate, decreased sperm counts and Leydig cell proliferation in the testes at 60 mg/kg and 200 mg/kg."1.31Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 5). Effects of repeated doses of flutamide for 2 and 4 weeks. ( Ikuse, T; Nomura, A; Okahara, A; Sakamoto, H; Tanioka, H; Yamashita, K, 2000)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Laue, L1
Merke, DP2
Jones, JV2
Barnes, KM1
Hill, S2
Cutler, GB2
Keil, MF1
Fields, J1
Pazos, F1
Sánchez-Franco, F1
Balsa, JA1
Escalada, J1
Palacios, N1
Cacicedo, L1
Okahara, A1
Nomura, A1
Tanioka, H1
Sakamoto, H1
Yamashita, K1
Ikuse, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia[NCT00529841]7 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for flutamide and Weight Gain

ArticleYear
A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
    The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:10

    Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Bone Dev

1996
Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.
    The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:3

    Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Anti-Inflammatory Agents; Antineop

2000

Other Studies

2 other studies available for flutamide and Weight Gain

ArticleYear
Mechanisms of reduced body growth in the pubertal feminized male rat: unbalanced estrogen and androgen action on the somatotropic axis.
    Pediatric research, 2000, Volume: 48, Issue:1

    Topics: Aging; Androgen Receptor Antagonists; Animals; Flutamide; Gene Expression Regulation; Growth Hormone

2000
Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 5). Effects of repeated doses of flutamide for 2 and 4 weeks.
    The Journal of toxicological sciences, 2000, Volume: 25 Spec No

    Topics: Administration, Oral; Androgen Antagonists; Animals; Dose-Response Relationship, Drug; Flutamide; Ma

2000